Atrium Health Levine Cancer Institute | Strategic Alliance Partners

Nilanjan Ghosh, MD, PhD, discusses the expanded access second-line lisocabtagene maraleucel affords patients with large B-cell lymphoma.

“Second-line maintenance therapy is going to be incredibly important for patients because we know that once a patient with ovarian cancer recurs, their disease is incurable."

Financial toxicity has been linked to increased mortality rates, but can be improved with financial intervention for patients.

Clinicians should consider patient-related factors, disease-related factors, and prior therapies before deciding on a treatment regimen for patients with relapsed/refractory myeloma.

Molecular testing has led to monumental strides in the field of ovarian cancer, offering women with the disease more personalized treatment options.